Related Experiment Video

Updated: Apr 16, 2026

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy
11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy

Published on: April 29, 2014

17.3K

Future perspectives for mTOR inhibitors in renal cell cancer treatment

Anna M Czarnecka1, Anna Kornakiewicz, Fei Lian

  • 1Department of Oncology with Laboratory of Molecular Oncology, Military Institute of Medicine, Szaserow 128, 04-141, Warsaw, Poland.

Future Oncology (London, England)
|March 12, 2015
PubMed

Insights

Everolimus improves progression-free survival in metastatic renal cell carcinoma patients. This study explores targeting cancer stem cells and novel antiangiogenic therapies for enhanced efficacy.

Area of Science:

  • Oncology
  • Pharmacology
  • Cancer Biology

Background:

  • Metastatic renal cell carcinoma (mRCC) remains a significant clinical challenge.
  • Everolimus, a mammalian target of rapamycin (mTOR) inhibitor, exhibits antitumor and antiangiogenic properties.
  • Prior therapies like sunitinib and sorafenib have limitations in efficacy and toxicity.

Purpose of the Study:

  • To evaluate the efficacy of everolimus in patients with mRCC who progressed on prior therapies.
  • To explore novel therapeutic strategies targeting cancer stem cells (CSCs) in renal cell carcinoma (RCC).
  • To discuss emerging antiangiogenic therapies and the potential of systems biology in drug discovery for RCC.

Main Methods:

  • Randomized Phase III clinical trial comparing everolimus to best supportive care in mRCC patients.
  • Review and discussion of emerging concepts in cancer stem cell targeting and antiangiogenic therapies.
  • Exploration of systems biology and reverse molecular engineering for drug discovery in RCC.

Main Results:

  • Everolimus demonstrated a significant improvement in progression-free survival (PFS) compared to best supportive care.
  • The study highlights the potential of targeting mTOR pathways in specific cancer cell populations.

Conclusions:

  • Everolimus offers a valuable treatment option for patients with advanced RCC post-sunitinib/sorafenib progression.
  • Targeting renal cell carcinoma cancer stem cells presents a promising avenue for novel mTOR inhibitor therapies.
  • Systems biology approaches may accelerate drug discovery and development for renal cell carcinoma.
Keywords:
RAD001RECORDafinitorcombination treatmenteverolimusmTORrenal cell cancer

More Related Videos

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

14.4K
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.9K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.8K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K